Piperacillin Sulbactam Research Articles

Puerperal Sepsis Caused by Clostridium Innocuum in a Patient with Placenta Accreta and Literature Review

Puerperal Sepsis Caused by Clostridium Innocuum in a Patient with Placenta Accreta and Literature Review

Clinical efficacy and safety of silver nanoparticlebased disinfectant combined with piperacillin sodium and sulbactam sodium in the treatment of lower respiratory tract infection

This study evaluated the clinical efficacy and safety of piperacillin sulbactam in the treatment of lower respiratory tract infections, as well as the efficacy of silver nanoparticle-based disinfectant in equipment disinfection to reduce exogenous infection. From May 2018 to November 2018, 100 patients that had been diagnosed with a lower respiratory tract infection and hospitalized were divided into an experimental group and a control group. The experimental group was given piperacillin/sulbactam, and the control group was given mezlocillin/sulbactam, where 5.0 g was added to 100 mL of normal saline and administered via intravenous drip twice a day over a treatment course of 14 days. The cure rate of the experimental and control groups were 65.22% and 56.52% respectively. The efficacy rate was 91.30% and 91.30% respectively, with no significant difference between the two groups (P > 0.05). The results indicated that piperacillin/sulbactam is a safe, effective treatment for lower respiratory tract infections in elderly patients, the equipment was sterilized with silver nanoparticle-based disinfectant to reduce the incidence of adverse reactions and exogenous infections.

Distribution of pathogens and drug resistance of puerperal infection in 41 twin pregnancies

Objective The distribution and drug resistance of pathogenic bacteria of the twin pregnancy with puerperal infection were analyzed. Methods 41 twin pregnancy cases with puerperal infection were screened out and the clinical data were retrospectively analyzed. Results A total of 48 main pathogenic bacteria were detected, including 21 Gram-positive bacteria: 9 Staphylococcus aureus (18.8%), 7 Streptococcus hemolyticus (14.6%) and 5 Enterococcus faecalis (10.4%); 27 Gram-negative bacteria: 12 Escherichia coli (25.0%), 8 Aerogenic Enterobacter (16.7%) and 7 Gardnerella vaginalis (14.6%). Drug resistance: 3 kinds of Gram-positive bacteria were strongly resistant to ceftazidime, and were sensitive to piperacillin sulbactam. Staphylococcus aureus and Streptococcus hemolytic streptococcus were sensitive to clindamycin, and Enterococcus faecalis was strongly resistant to penicillin. 3 kinds of Gram-negative bacteria were sensitive to gentamicin and were strongly resistant to ampicillin and cefazolin. Escherichia coli and Enterobacteriaceae were sensitive to cefepime, and Gardnerella vaginalis were sensitive to levofloxacin, and were strongly resistant to cefepime. The main pathogenic bacteria were sensitive to meropenem and vancomycin. Conclusions According to the distribution and drug resistance of pathogens, we should rationally choose antimicrobial agents to prevent and cure puerperal infection of twin pregnancy. Key words: Twins; Puerperal infection/MI; Microbial sensitivity tests; Drug resistance, bacterial

Efficacy of Reduning injection combined with piperacillin sulbactam in the treatment of community acquired pneumonia

Objective To observe the clinical efficacy and safety of Reduning injection combined with piperacillin sulbactam in the treatment of community acquired pneumonia(CAP). Methods 122 cases with CAP were randomly divided into treatment group and control group by digital table method.The two groups were given piperacillin sodium and sulbactam sodium 3.75g, once every 12 hours, course 7-10d.The treatment group was treated with Reduning injection, 20ml/d treatment for 7-10d.The clinical symptoms of the two groups before and after treatment, the total number of white blood cells(WBC) and C reactive protein(CRP) to resume normal time were observed. Results The effective rate was 94.91% in the treatment group and 80% in the control group, the difference between the two groups was statistically significant(χ2=10.286, P<0.05). The treatment group was significantly shorter than the control group in controlling fever and cough symptoms(all P<0.05).3 months after treatment, the WBC and CRP recovery to the normal rate of the two groups had statistically significant differences (χ2=2.880, 3.926, all P<0.05). No obvious toxic side effects and adverse reactions were observed in the two groups. Conclusion Reduning injection combined with piperacillin sodium and sulbactam sodium in the treatment of CAP can alleviate the clinical symptoms of fever.This method has good clinical curative effect and high safety.It can be used as an effective method for treatment of CAP. Key words: Pneumonia; Community-acquired infections; Reduning injection; Piperacillin sodium and sulbactam sodium

Differences in efficacy of piperacillin sulbactam sodium and moxifloxacin in community-acquired pneumonia

Objective To investigate the differences of piperacillin sulbactam sodium and moxifloxacin in community-acquired pneumonia (CAP).Methods A analysis of 140 cases of CAP patients,were randomly divided into two groups,of which 70 cases piperacillin sulbactam sodium; remaining 70 cases moxifloxacin comparative clinical efficacy.Results The moxifloxacin group therapy effective rate of 88.57％ greater than 68.57％ of the piperacillin,the differences were statistically significant(P＜0.05).Conclusions Moxifloxacin in the treatment of CAP more effective than piperacillin sulbactam sodium,and the appropriate cost worth in clinical practice,patients Adaptation and contraindications. Key words: piperacillin sulbactam sodium; moxifloxacin; CAP

Piperacillin–sulbactam versus piperacillin–tazobactam: a multicentre, randomised, single-blind, controlled clinical trial

The objective of this study was to compare the efficacy and safety of piperacillin–sulbactam (PIP–SBT) and piperacillin–tazobactam (PIP–TAZ) in the treatment of bacterial respiratory and urinary tract infections. A randomised, single-blind, controlled clinical trial was performed. Differences in clinical efficacy, bacteriology and safety between the two groups were subjected to statistical analysis, including intent-to-treat (ITT) analysis. A total of 215 cases were enrolled, with 203 complete cases (99 PIP–SBT, 104 PIP–TAZ). A total of 209 cases (103 PIP–SBT, 106 PIP–TAZ) were included in the ITT analysis and a total of 212 cases (104 PIP–SBT, 108 PIP–TAZ) were included in the safety analysis. Overall efficacy rates of PIP–SBT and PIP–TAZ were 93.2% and 93.4%, respectively. Overall bacterial eradication rates of the two groups were 95% and 97.59%, respectively. Among the PIP–SBT group, eight patients (7.69%) had adverse events, including four probable drug-related events. Among the PIP–TAZ group, nine patients (8.33%) had adverse events, including one definitely drug-related and four probable drug-related events. All differences between the two groups were insignificant. PIP–SBT could be a suitable replacement for PIP–TAZ in the therapy of community-acquired respiratory and urinary tract infections caused by β-lactamase-producing bacterial isolates.

Comparative in vitro activity of piperacillin, piperacillin–sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients

We investigated the antimicrobial activity of piperacillin-tazobactam versus piperacillin-sulbactam against common nosocomial pathogens (n = 565) isolated from intensive care patients. For Gram-positive bacteria, antimicrobial susceptibilities to the two piperacillin-beta-lactamase inhibitor combinations were almost identical. For Gram-negative bacteria, piperacillin-tazobactam exhibited greater activity against Escherichia coli and Proteus vulgaris than piperacillin-sulbactam. Both combinations, however, were equally effective against the other Enterobacteriaceae and Pseudomonas aeruginosa isolates. Piperacillin-sulbactam exhibited better antimicrobial activity against Acinetobacter baumannii. Our findings might prove important for the appropriate choice of antibiotic therapy with beta-lactam-beta-lactamase inhibitor combinations.